REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)

Inclusion Criteria: Both nondiabetic patients and patients with non-insulin-requiring type 2 diabetes mellitus admitted with a suspected AMI are eligible if they meet the following criteria: * Signs or symptoms of AMI with definite ECG changes, defined as persistent ST-segment elevation (\> or = than 1 mm)in two or more contiguous leads, or new left bundle branch block * Onset of symptoms within 24 hours before hospital presentation * Capillary blood glucose level on presentation \> or = 8.0 mmol/L (144 mg/dL) Exclusion Criteria: * Patient with conditions that REQUIRE the administration of insulin, including: * Type 1 diabetes mellitus, defined by a documented history of diabetes mellitus before the age of 30 * Type 2 diabetes mellitus that was treated with insulin prior to AMI presentation * Type 2 diabetes mellitus that is known to be very poorly controlled (e.g. admission capillary blood glucose \> 16.0 mmol/L (288 mg/dL)or marked elevation in glucose for which the site investigator plans to treat with insulin therapy) * A history of severe hypoglycemic episodes (defined as hypoglycemia with symptoms which the patient is unable to reverse without the assistance of another person) within the past two years * Known or suspected end-stage liver disease (due to the risk of hypoglycemia in the setting of liver dysfunction and consequent impaired regulation of glucose homeostasis) * Cardiogenic shock on admission (due to the inaccuracy of glucose meter readings) * Documented pregnancy * Any concomitant disease (e.g. cancer) that might limit life expectancy to less than 90 days * Anticipated poor adherence with study treatments or an other factor that might jeopardize 90-day follow-up (e.g. no fixed address, long distance to hospital, etc.) * Prior enrollment in this trial or current enrollment in another trial of ST-segment elevation myocardial infarction